Insider · CIK 0001267487
Kathy L Hibbs
Files at LAB (STANDARD BIOTOOLS INC.), ME (23andMe Holding Co.), SLGC (SomaLogic, Inc.), SOPH (SOPHiA GENETICS SA). First filing Dec 6, 2022, latest Sep 10, 2026.
In brief
Kathy L Hibbs files SEC Form 4 as director and officer at ME (23andMe Holding Co.), and also at SOPH (SOPHiA GENETICS SA), LAB (STANDARD BIOTOOLS INC.), SLGC (SomaLogic, Inc.). Since Dec 6, 2022, Kathy L Hibbs has reported 0 open-market buys worth $0 and 19 open-market sells worth $631k, the latest filed on Sep 10, 2026.
A track record needs three past buys with six months of prices behind them; Kathy L Hibbs has 0, so none is measured yet.
The newest scored trade: sold $51k of SOPH on Sep 8, 2026, filed Sep 10, 2026, scored 17 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 3 sells worth $140k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SOPH: SOPHiA GENETICS SA
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 17Weak | SOPHiA GENETICS SA | $51k 6,250 shares | -6% | +168% from low-6% from high | |
| 17Weak | SOPHiA GENETICS SA | $54k 6,250 shares | -6% | +177% from low0% from high | |
| 16Weak | SOPHiA GENETICS SA | $35k 7,508 shares | -8% | +62% from low-16% from high | |
| 0Weak | 23andMe Holding Co. | $19k 38,551 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $18k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $19k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $18k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $20k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $23k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $30k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $28k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $28k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $36k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $37k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $34k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $30k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $33k 38,548 shares | -3% | - | |
| 0Weak | 23andMe Holding Co. | $31k 38,548 shares | -3% | - | |
| 9Weak | 23andMe Holding Co. | $85k 26,259 shares | -10% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 25, 2026 | SOPH SOPHIA GENETICS SA | 18,750 0.02% of outstanding | $158k | Aug 25, 2026 | none |
| Mar 10, 2026 | SOPH SOPHIA GENETICS SA | 15,508 0.02% of outstanding | $69k | Mar 10, 2026 | none |
| Nov 3, 2025 | SOPH SOPHIA GENETICS SA | 10,000 0.01% of outstanding | $50k | Nov 3, 2025 | none |
| Jun 30, 2025 | SOPH SOPHiA GENETICS SA | 10,000 0.01% of outstanding | $31k | Jun 30, 2025 | none |
| Sep 9, 2024 | SOPH SOPHIA GENETICS SA | 16,080 0.02% of outstanding | $60k | Sep 9, 2024 | $50k |
| Aug 9, 2024 | SOPH SOPHIA GENETICS SA | 15,777 0.02% of outstanding | $53k | Aug 9, 2024 | $13k |
| Jun 13, 2024 | ME 23andMe Holding Co. | 50,462 0.02% of outstanding | $21k | Jun 13, 2024 | $152k |
| Jun 6, 2024 | ME 23andMe Holding Co. | 192,288 0.06% of outstanding | $79k | Jun 6, 2024 | $92k |
| May 10, 2024 | SOPH SOPHiA GENETICS SA | 2,780 0.00% of outstanding | $13k | May 10, 2024 | $13k |
| Mar 8, 2024 | SOPH SOPHIA GENETICS SA | 2,777 0.00% of outstanding | $14k | Mar 8, 2024 | none |
| Mar 7, 2024 | ME 23ANDME HOLDING CO | 192,743 0.06% of outstanding | $100k | Mar 7, 2024 | $182k |
| Nov 30, 2023 | ME 23ANDME HOLDING CO CLASS A | 269,836 0.09% of outstanding | $242k | Nov 30, 2023 | $209k |
| Nov 2, 2023 | ME 23ANDME HOLDING CO CLASS A | 77,096 0.03% of outstanding | $63k | Nov 2, 2023 | $243k |
| Oct 19, 2023 | ME 23ANDME HOLDING CO CLASS A | 38,548 0.02% of outstanding | $31k | Oct 19, 2023 | $289k |
Transactions
The newest 50 of 64 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -6,250 | $8.13 | $51k | 96,992 | 35 d ago |
| Aug 25, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -6,250 | $8.68 | $54k | 103,242 | Aug 26, 2026 |
| Jun 18, 2026 | LAB STANDARD BIOTOOLS INC. | AGrant or award Common Stock | +99,116 | $0.00 | $0 | 236,836 | Jun 23, 2026 |
| Jun 18, 2026 | LAB STANDARD BIOTOOLS INC. | AGrant or award Stock Option (Right to buy)derivative | +175,923 | $0.00 | $0 | 175,923 | Jun 23, 2026 |
| Jun 18, 2026 | SOPH SOPHiA GENETICS SA | AGrant or award Ordinary Shares | +19,724 | $5.46 | $108k | 109,492 | Jun 22, 2026 |
| Jun 18, 2026 | SOPH SOPHiA GENETICS SA | AGrant or award Share Option (Right to Buy)derivative | +28,818 | $5.46 | $157k | 218,569 | Jun 22, 2026 |
| May 12, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares10b5-1 | -7,508 | $4.67 | $35k | 89,768 | May 13, 2026 |
| Jun 20, 2025 | LAB STANDARD BIOTOOLS INC. | AGrant or award Common Stock | +94,592 | $0.00 | $0 | 137,720 | Jun 24, 2025 |
| Jun 20, 2025 | LAB STANDARD BIOTOOLS INC. | AGrant or award Stock Option (Right to buy)derivative | +125,660 | $0.00 | $0 | 125,660 | Jun 24, 2025 |
| Jun 28, 2024 | LAB STANDARD BIOTOOLS INC. | AGrant or award Common Stock | +43,128 | $0.00 | $0 | 43,128 | Jul 2, 2024 |
| Jun 28, 2024 | LAB STANDARD BIOTOOLS INC. | AGrant or award Stock Option (Right to buy)derivative | +72,213 | $0.00 | $0 | 72,213 | Jul 2, 2024 |
| May 20, 2024 | ME 23andMe Holding Co. | FTax withholding Class A Common Stock | -35,282 | $0.55 | $19k | 1,217,033 | May 21, 2024 |
| May 2, 2024 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,551 | $0.42 | $16k | 1,290,866 | May 6, 2024 |
| May 2, 2024 | ME 23andMe Holding Co. | SOpen-market sale Class A Common Stock10b5-1 | -38,551 | $0.49 | $19k | 1,252,315 | May 6, 2024 |
| May 2, 2024 | ME 23andMe Holding Co. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,551 | $0.00 | $0 | 0 | May 6, 2024 |
| Apr 18, 2024 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,548 | $0.42 | $16k | 1,290,863 | Apr 19, 2024 |
| Apr 18, 2024 | ME 23andMe Holding Co. | SOpen-market sale Class A Common Stock10b5-1 | -38,548 | $0.47 | $18k | 1,252,315 | Apr 19, 2024 |
| Apr 18, 2024 | ME 23andMe Holding Co. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,548 | $0.00 | $0 | 38,551 | Apr 19, 2024 |
| Apr 4, 2024 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,548 | $0.42 | $16k | 1,290,863 | Apr 5, 2024 |
| Apr 4, 2024 | ME 23andMe Holding Co. | SOpen-market sale Class A Common Stock10b5-1 | -38,548 | $0.50 | $19k | 1,252,315 | Apr 5, 2024 |
| Apr 4, 2024 | ME 23andMe Holding Co. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,548 | $0.00 | $0 | 77,099 | Apr 5, 2024 |
| Mar 21, 2024 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,548 | $0.42 | $16k | 1,290,863 | Mar 22, 2024 |
| Mar 21, 2024 | ME 23andMe Holding Co. | SOpen-market sale Class A Common Stock10b5-1 | -38,548 | $0.46 | $18k | 1,252,315 | Mar 22, 2024 |
| Mar 21, 2024 | ME 23andMe Holding Co. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,548 | $0.00 | $0 | 115,647 | Mar 22, 2024 |
| Mar 7, 2024 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,548 | $0.42 | $16k | 1,290,863 | Mar 11, 2024 |
| Mar 7, 2024 | ME 23andMe Holding Co. | SOpen-market sale Class A Common Stock10b5-1 | -38,548 | $0.53 | $20k | 1,252,315 | Mar 11, 2024 |
| Mar 7, 2024 | ME 23andMe Holding Co. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,548 | $0.00 | $0 | 154,195 | Mar 11, 2024 |
| Feb 22, 2024 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,548 | $0.42 | $16k | 1,278,375 | Feb 23, 2024 |
| Feb 22, 2024 | ME 23andMe Holding Co. | SOpen-market sale Class A Common Stock10b5-1 | -38,548 | $0.61 | $23k | 1,239,827 | Feb 23, 2024 |
| Feb 22, 2024 | ME 23andMe Holding Co. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,548 | $0.00 | $0 | 192,743 | Feb 23, 2024 |
| Feb 20, 2024 | ME 23andMe Holding Co. | FTax withholding Class A Common Stock10b5-1 | -40,522 | $0.72 | $29k | 1,239,827 | Feb 21, 2024 |
| Feb 15, 2024 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,548 | $0.42 | $16k | 1,318,897 | Feb 16, 2024 |
| Feb 15, 2024 | ME 23andMe Holding Co. | SOpen-market sale Class A Common Stock10b5-1 | -38,548 | $0.78 | $30k | 1,280,349 | Feb 16, 2024 |
| Feb 15, 2024 | ME 23andMe Holding Co. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,548 | $0.00 | $0 | 231,291 | Feb 16, 2024 |
| Jan 25, 2024 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,548 | $0.42 | $16k | 1,318,897 | Jan 26, 2024 |
| Jan 25, 2024 | ME 23andMe Holding Co. | SOpen-market sale Class A Common Stock10b5-1 | -38,548 | $0.73 | $28k | 1,280,349 | Jan 26, 2024 |
| Jan 25, 2024 | ME 23andMe Holding Co. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,548 | $0.00 | $0 | 269,839 | Jan 26, 2024 |
| Jan 11, 2024 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,548 | $0.42 | $16k | 1,318,897 | Jan 12, 2024 |
| Jan 11, 2024 | ME 23andMe Holding Co. | SOpen-market sale Class A Common Stock10b5-1 | -38,548 | $0.72 | $28k | 1,280,349 | Jan 12, 2024 |
| Jan 11, 2024 | ME 23andMe Holding Co. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,548 | $0.00 | $0 | 308,387 | Jan 12, 2024 |
| Jan 5, 2024 | LAB STANDARD BIOTOOLS INC. | AGrant or award Common Stock | +79,412 | $0.00 | $0 | 79,412 | Jan 9, 2024 |
| Jan 5, 2024 | SLGC SomaLogic, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -185,400 | - | - | 0 | Jan 9, 2024 |
| Jan 5, 2024 | LAB STANDARD BIOTOOLS INC. | AGrant or award Stock Option (Right to buy)derivative | +205,794 | - | - | 205,794 | Jan 9, 2024 |
| Dec 28, 2023 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,548 | $0.42 | $16k | 1,318,897 | Dec 29, 2023 |
| Dec 28, 2023 | ME 23andMe Holding Co. | SOpen-market sale Class A Common Stock10b5-1 | -38,548 | $0.93 | $36k | 1,280,349 | Dec 29, 2023 |
| Dec 28, 2023 | ME 23andMe Holding Co. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,548 | $0.00 | $0 | 346,935 | Dec 29, 2023 |
| Dec 14, 2023 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,548 | $0.42 | $16k | 1,318,897 | Dec 18, 2023 |
| Dec 14, 2023 | ME 23andMe Holding Co. | SOpen-market sale Class A Common Stock10b5-1 | -38,548 | $0.97 | $37k | 1,280,349 | Dec 18, 2023 |
| Dec 14, 2023 | ME 23andMe Holding Co. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -38,548 | $0.00 | $0 | 385,483 | Dec 18, 2023 |
| Nov 30, 2023 | ME 23andMe Holding Co. | MOption exercise Class A Common Stock10b5-1 | +38,548 | $0.42 | $16k | 1,318,897 | Dec 1, 2023 |
Questions about Kathy L Hibbs
Answered from the filings on this page, as of the latest one.
Is Kathy L Hibbs buying or selling?
In the last 12 months Kathy L Hibbs reported 0 open-market buys worth $0 and 3 open-market sells worth $140k on SEC Form 4; the latest was sold $51k of SOPH on Sep 8, 2026. Grants, option exercises and tax withholding are not counted.
How did Kathy L Hibbs's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kathy L Hibbs has 0.
Where does Kathy L Hibbs file Form 4?
Kathy L Hibbs has filed Form 4 at ME (23andMe Holding Co.) as Chief Administrative Officer; SOPH (SOPHiA GENETICS SA); LAB (STANDARD BIOTOOLS INC.); SLGC (SomaLogic, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.